Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hvidovre University Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
Both GLP-2 and GIP reduce the bone resorption (measured as CTX) in healthy persons. In this study, we will investigate wether GLP-2 and GIP is reducing CTX in persons with type 2 diabetes.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| GLP-2 | Experimental | Glucagon-like peptide 2 |
|
| GIP | Experimental | Glucose-dependent insulinotropic polypeptide |
|
| Placebo | Placebo Comparator | Saline |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| GLP-2 | Other | GLP-2 injection |
| |
| GIP |
| Measure | Description | Time Frame |
|---|---|---|
| CTX | Bone resorption measured as collagen type 1 C-terminal telopeptide (CTX) in serum. | -10 minutes to 240 minutes |
| P1NP | Bone formation measured as procollagen type 1 N-terminal propeptide (P1NP) in serum. | -10 minutes to 240 minutes |
| Measure | Description | Time Frame |
|---|---|---|
| PTH | PTH measured in serum | -10 minutes to 240 minutes |
| Sclerostin | Bone marker. | -10 min to 240 min. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mette Rosenkilde, MD | University of Copenhagen | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hvidovre University Hospital | Hvidovre | 2650 | Denmark |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| D001862 | Bone Resorption |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
The study is a crossover study with the following interventions: GLP-2, GIP, and placebo.
Not provided
Not provided
Not provided
| Other |
GIP injection |
|
| Placebo | Other | Placebo injection |
|
| Glucose | Measured in serum | -10 minutes to 240 minutes |
| Insulin | Measured in serum | -10 minutes to 240 minutes |
| C-peptide | Measured in serum | -10 minutes to 240 minutes |
| GIP | Glucose-dependent insulinotropic polypeptide measured in plasma. | -10 minutes to 240 minutes |
| GLP-2 | Glucagon-like peptide 2 measured in plasma. | -10 minutes to 240 minutes |
| Glucagon | Glucagon measured in plasma | -10 minutes to 240 minutes |
| Blood pressure | Measured before blood sampling | -10 minutes to 240 minutes |
| Heart rate | Measured before blood sampling | -10 minutes to 240 minutes |
| D004700 | Endocrine System Diseases |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |